AccessibilityHelpAbout Us
Evaxion A/s logo

Evaxion A/s(NASDAQ) EVAX

Market Cap$27.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-99%
1 Year+8%
1 Month+4%
$3.27
+1.55%
+0.05Today
Evaxion A/s last closing stock price
MetricPriceDate
Last closeUSD 3.272026-09-18
Evaxion A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.47%USD 3.132026-09-11
1 month+3.81%USD 3.152026-08-19
3 month+7.21%USD 3.052026-06-18
Year to date-31.45%USD 4.772025-12-31
1 year+8.28%USD 3.022025-09-18
3 year-86.38%USD 24.002023-09-19
5 year-99.24%USD 429.002021-09-17
Since inception-99.34%USD 494.502021-02-05

Evaxion A/s Financials at a Glance

Market Cap

$27.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$7.49M

Net Income (TTM)

-$8.65M

EPS (TTM)

-$1.05

P/E Ratio

-3.10

Dividend

$0.00

Beta (Volatility)

0.64 (Low)

Price

$3.27

Volume

43,342.582

Open

$3.22

Previous Close

$3.27

Daily Range

$3.16 - $3.33

52-Week Range

$2.77 - $12.15

Estimated Earnings Date

Nov 5, 2026

EVAX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evaxion A/s

Evaxion Biotech A/S is a clinical-stage biotechnology firm focused on developing artificial intelligence-driven immunotherapies. The company aims to address significant health challenges, including cancers, bacterial infections, and viral diseases through its innovative pipeline.

Products and Services
  • EVX-01: Phase IIb cancer immunotherapy for metastatic melanoma
  • EVX-02: DNA-based immunotherapy in Phase IIa trials for adjuvant melanoma
  • EVX-B1, EVX-B2, EVX-V1: Pre-clinical vaccine candidates targeting various pathogens
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Potential market expansion in oncology and infectious diseases
  • AI-driven technology enhances drug development efficiency
Financial Highlights
  • Recent quarterly net income of -$3.73 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of approximately $13.99 million as of June 30, 2026
  • Current ratio of 5.06 indicates strong liquidity position
Evaxion Biotech A/S is positioned in the biotechnology sector, leveraging artificial intelligence to innovate in immunotherapy. The company has a promising pipeline, particularly in oncology, with several candidates undergoing clinical trials. The focus on AI technology not only enhances the efficiency of drug development but also positions the company favorably in a competitive market. Financially, the company is currently operating at a loss, which is typical for clinical-stage biotech firms investing heavily in research and development. The recent quarterly results show a net income loss, but the liquidity position remains strong with significant cash reserves. The current ratio indicates that the company can cover its short-term liabilities comfortably, which is crucial for sustaining operations during the development phase. Overall, Evaxion Biotech A/S presents an intriguing opportunity for investors interested in the biotechnology sector, particularly those focused on innovative approaches to healthcare challenges. The combination of a robust product pipeline and a strong liquidity position may appeal to those looking for growth potential in the biotech industry.
AI Generated • Sep 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

46

CEO

Helena Katrina Tayton-Martin, PhD, MBA

Website

www.evaxion-biotech.com

Headquarters

Horsholm, ND 2970, DK

EVAX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-115.98%

Net Income Margin

-115.49%

Return on Equity

-61.39%

Return on Capital

-37.62%

Return on Assets

-44.65%

Earnings Yield

-32.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$27.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.34M

Volume

43.34K

Avg. Volume

199.44K

Financials (TTM)

Gross Profit

$7.49M

Operating Income

-$8.69M

EBITDA

-$9.93M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$14.00M

Total Debt

$7.10M

Evaxion A/s Performance Analysis

Evaxion A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 73,112N/A
20242024-12-31USD 3,338,6364466.5%
20252025-12-31USD 7,551,041126.2%
Evaxion A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020148.6%
Q42025-12-31-100.0%
Q12026-03-31N/A
Q22026-06-30N/A
Evaxion A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -49.03-22.0%
20232023-12-31USD -40.53-17.3%
20242024-12-31USD -9.83-75.7%
20252025-12-31USD -1.21-87.7%
Evaxion A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30195.5%
Q42025-12-31-121.2%
Q12026-03-3150.6%
Q22026-06-30-1945.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$27.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$592.88K

N/A

Employees

46

N/A

Net Income

-$3.72M

+22.9%

EBITDA

-$3.84M

+19.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$14.00M

-5.1%

Total Debt

$7.10M

-37.0%

Accounts Receivable

$1.86M

+115.0%

Inventory

$0.00

N/A

Long Term Debt

$6.56M

-38.9%

Short Term Debt

$541.99K

+0.4%

Return on Assets

-44.65%

N/A

Return on Invested Capital

-53.48%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MURAMural Oncology plc
$2.04+0.00%
GBIOGeneration Bio Co.
$5.34+0.00%
CELUCelularity Inc.
$1.31+3.15%
VERUVeru Inc.
$2.41+0.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About EVAX

What is the current price of Evaxion A/s?

Evaxion A/s is trading at $3.27 per share.

What is the 52-week range for Evaxion A/s?

Over the past 52 weeks, Evaxion A/s has traded between $2.77 and $12.15.

How much debt does Evaxion A/s have?

As of the most recent reporting period, Evaxion A/s reported total debt of $7.10M.

How much cash does Evaxion A/s have on hand?

Evaxion A/s reported $14.00M in cash and cash equivalents in its most recent financial results.

What is Evaxion A/s’s dividend yield?

Evaxion A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services